* Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna , Vienna.
Climacteric. 2014 Feb;17(1):92-6. doi: 10.3109/13697137.2013.800040. Epub 2013 Jun 28.
We evaluated dehydroepiandrosterone sulfate (DHEAS) levels in premature ovarian failure (POF) patients with and without Hashimoto's thyroiditis, and the impact of DHEA supplementation on thyroid autoantibodies. In a retrospective case series, we included 67 women with spontaneous POF who received estrogen/gestagen replacement with or without DHEA (30 mg/day) for 3 months. Women who were seropositive for thyroglobulin antibodies and/or thyroperoxidase autoantibodies (n = 30) revealed lower pretherapeutic DHEAS levels (1.2 μg/ml, range 0.4-2.9 μg/ml vs. 1.9 μg/ml, range 0.2-3.9 μg/ml; p < 0.001). DHEAS showed an inverse correlation with both thyroglobulin antibodies (r = -0.426, p < 0.001) and thyroperoxidase autoantibodies (r = -0.362, p = 0.002). When treated with additional DHEA, significant decreases were found for thyroperoxidase autoantibodies (median 85.0 IU/ml, range 41-600 IU/ml vs. median 51.0 IU/ml, range 20-589 IU/ml; p = 0.005) but not for thyroglobulin antibodies.
我们评估了伴有和不伴有桥本甲状腺炎的卵巢早衰（POF）患者的硫酸脱氢表雄酮（DHEAS）水平，以及 DHEA 补充对甲状腺自身抗体的影响。在一项回顾性病例系列研究中，我们纳入了 67 名接受雌激素/孕激素替代治疗的自发性 POF 女性，其中 30 名同时接受 DHEA（30mg/天）治疗 3 个月。甲状腺球蛋白抗体和/或甲状腺过氧化物酶自身抗体阳性的女性（n=30）的治疗前 DHEAS 水平较低（1.2μg/ml，范围 0.4-2.9μg/ml 与 1.9μg/ml，范围 0.2-3.9μg/ml；p<0.001）。DHEAS 与甲状腺球蛋白抗体（r=-0.426，p<0.001）和甲状腺过氧化物酶自身抗体（r=-0.362，p=0.002）呈负相关。当接受额外的 DHEA 治疗时，甲状腺过氧化物酶自身抗体显著下降（中位数 85.0IU/ml，范围 41-600IU/ml 与中位数 51.0IU/ml，范围 20-589IU/ml；p=0.005），但甲状腺球蛋白抗体没有下降。
Zotero 插件